-

Jury Finds in Favor of Monsanto in Philadelphia Trial

Young decision marks 14th favorable outcome in last 20 trials for Company

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, the jury reached a verdict in the Young Roundup™ product liability trial before Judge Angelo Foglietta in the Philadelphia Court of Common Pleas.

In response to the decision, Monsanto issued the following statement:

“The jury’s verdict in favor of the Company marks the 14th favorable outcome in the last 20 trials and validates the Company’s strategy of taking cases to trial based on strong scientific and regulatory evidence. The verdict makes clear that the plaintiff failed to prove that Roundup™ was the cause of the injuries alleged in this case, consistent with the scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide. While we have great sympathy for anyone who suffers a loss or injury, the science proves that Roundup™ is not carcinogenic.

“This verdict follows the favorable ruling from the Third Circuit Court of Appeals in Schaffner v. Monsanto, which unanimously held that the state-based failure-to-warn claims central to these cases are expressly preempted by the federal law, since the U.S. EPA has repeatedly concluded the product does not cause cancer and approved the product label without any such warning. The Company is actively taking steps to apply the Schaffner ruling to other Roundup™ cases and looks forward to presenting its arguments, as fully embraced by the Third Circuit, at trial courts, appellate courts, and the U.S. Supreme Court.

“Additionally, outside the courtroom, we will continue supporting legislation at the state and federal level alongside hundreds of agricultural organizations to ensure that any pesticide reviewed and registered by the U.S. EPA – and sold under a label consistent with the EPA’s determinations – is sufficient to satisfy requirements for health and safety warnings. Without legislative certainty, the litigation industry will continue to target crop protection tools that have been deemed safe by experts at the U.S. EPA.

“We continue to stand fully behind the safety of Roundup™ products – critical tools that farmers rely on to produce affordable food and feed the world.”

Contacts

Media
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Media
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand from Bayer, today announced a new formula for One A Day® Women's Multi Gummy, which now delivers 1,000 mcg of Biotin per serving (serving size is two gummies). The new formulation contains more biotin† with 2833% Daily Value (DV) than other leading multivitamin gummies including Olly Women’s Multi, Nature Made Women's Advanced Multivitamin Gummies, and Vitafusion Women's Multi (1000 mcg vs 150 mcg), while continu...

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched health systems, according to new research by Economist Enterprise. The research, supported by Bayer and published in a report titled “Making self-care work: integrating self-care into health systems”, cites existing evidence estimating that self-care practices can deliver approximately US$ 179 bil...

Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials

DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry Ford Health’s comprehensive clinical research program and its deep connection to the communities it serves. “Clinical trials are often the first opportunity patients have to access cutting-edge treatments,” said Dr. David Lanfear, Chief Scie...
Back to Newsroom